Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival?

[1]  T. Freudenberger.  Lung Cancer: Principles and Practice, 3rd edition. , 2006 .

[2]  I. Ellis,et al.  Total loss of MHC class I is an independent indicator of good prognosis in breast cancer , 2005, International journal of cancer.

[3]  R. Schreiber,et al.  The three Es of cancer immunoediting. , 2004, Annual review of immunology.

[4]  F. Dammacco,et al.  β2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide1 , 2003, The Journal of Immunology.

[5]  Hein Putter,et al.  Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.

[6]  Francesco M Marincola,et al.  Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? , 2002, Journal of the National Cancer Institute.

[7]  R. Kiessling,et al.  HLA expression in uveal melanoma: there is no rule without some exception. , 2002, Human immunology.

[8]  Nanette Santoro,et al.  Where Are We Going , 1999 .

[9]  S Ferrone,et al.  HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. , 1999, Molecular medicine today.

[10]  D. Hicklin,et al.  Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. , 1999, The American journal of pathology.

[11]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[12]  A. Harris,et al.  Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. , 1996, British Journal of Cancer.

[13]  P. Stern,et al.  Natural history of HLA expression during tumour development. , 1993, Immunology today.

[14]  C. Marboe,et al.  Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues. , 1993, Journal of immunological methods.

[15]  J. Yewdell,et al.  Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.

[16]  M. R. Oliva,et al.  Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation. , 1991, Cancer research.

[17]  H. Ploegh,et al.  Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. , 1986, Journal of immunology.

[18]  J. Whelan,et al.  Striking paucity of HLA-A, B, C and beta 2-microglobulin on human neuroblastoma cell lines. , 1983, Journal of immunology.

[19]  O. Stutman.  Chemical carcinogenesis in nude mice: comparison between nude mice from homozygous matings and heterozygous matings and effect of age and carcinogen dose. , 1979, Journal of the National Cancer Institute.

[20]  C. Barnstable,et al.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis , 1978, Cell.

[21]  O. Stutman.  Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice , 1974, Science.

[22]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[23]  F. Marincola,et al.  Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. , 2000, Advances in immunology.

[24]  Harvey I. Pass,et al.  Lung cancer : principles and practice , 1996 .

[25]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.